DCF Valuation
Carl Zeiss Meditec AG (CZMWF) DCF Valuation — Is CZMWF undervalued?
The estimated DCF fair value of one Carl Zeiss Meditec AG (CZMWF) share is $59.20. Compared to the current market price of $34.71, the stock is undervalued by 70.5%.
DCF fair value
$59.20
Market price
$34.71
Upside / downside
+70.5%
Prefer the inverse question? See what growth rate the market is pricing into CZMWF →
Carl Zeiss Meditec AG (CZMWF) DCF valuation FAQ
What is the DCF fair value of Carl Zeiss Meditec AG (CZMWF)?
The discounted-cash-flow model estimates the intrinsic fair value of one Carl Zeiss Meditec AG (CZMWF) share at $59.20, based on a 10-year projection of its cash flows converging to Damodaran industry averages.
Is Carl Zeiss Meditec AG (CZMWF) overvalued or undervalued?
Against the current market price of $34.71, the DCF fair value of $59.20 implies CZMWF is undervalued by 70.5%.
How is the CZMWF DCF value calculated?
It is a 10-year discounted-cash-flow estimate built from Carl Zeiss Meditec AG's reported fundamentals, with terminal assumptions anchored to Damodaran NYU industry datasets. The market price refreshes daily; the DCF fair value updates when Carl Zeiss Meditec AG files a new quarterly or annual report.
How this CZMWF valuation is built
The model projects ten years of Carl Zeiss Meditec AG's free cash flow to the firm and discounts each year at its own cost of capital. Rather than assuming today's growth and margins persist forever, a moat-scoring step — weighing Carl Zeiss Meditec AG's ROIC-versus-WACC spread, gross-margin trend, and reinvestment efficiency — decides how many years the business holds its edge before its economics mean-revert toward the Damodaran NYU benchmarks for its industry.
WACC is rebuilt each year from an unlevered-then-relevered beta and the company's evolving capital structure; terminal value uses the Gordon growth model with a reinvestment rate tied to the return earned on new capital (goodwill stripped out to reflect operating efficiency). Every assumption — growth, margins, tax, leverage, convergence timing — is editable, and running the full interactive model adds a 10,000-draw Monte Carlo simulation and WACC-versus-terminal-growth sensitivity heatmaps.
The market price refreshes daily; the DCF fair value updates when Carl Zeiss Meditec AG files a new quarterly or annual report. For educational/informational purposes only — not investment advice. Last updated 2026-08-06.